02.05.2024

Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities

01.30.2024

Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance

01.26.2024

European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

01.10.2024

Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation

01.09.2024

TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer

01.08.2024

European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer

01.02.2024

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

12.19.2023

Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts

12.15.2023

PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer

12.14.2023

Pfizer Declares First-Quarter 2024 Dividend

12.14.2023

Pfizer Completes Acquisition of Seagen

12.13.2023

Pfizer Provides Full-Year 2024 Guidance